SK Biopharmaceuticals Co., Ltd. (326030.KS)

https://www.skbp.com

SK Biopharmaceuticals focuses on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts. SK Biopharmaceuticals is the first and only Korean company to independently develop and commercialize an antiseizure medication, cenobamate (brand name: XCOPRI®) in the U.S. More than 100,000 patients have been treated globally with cenobamate, developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, Inc., since its launch in the U.S. in 2020. Cenobamate has successfully entered five major regions: North America, Europe, Asia, Central and South America, and the Middle East and North Africa. The company also has a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. *

	Start	2019-02-14 existent
	Group	SK Group (Group)
	Industry	CNS drug (neurological drug)
	Industry 2	cenobamate

	Region	Seoul
	Country	Korea, Republic of
	City	n. a. Seoul
		Address record changed: 2024-07-18

Basic data	Employees	n. a.

		* Document for »About Section«: Full-Life Technologies. (7/17/24). "Press Release: Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors". Heidelberg & Seoul.

		Record changed: 2024-08-24